Ludwig Presence at 2016 AACR Annual Meeting Ludwig Scientist (s) Affiliation (s) Session Time Location Session Type Session Title Presentation/Abstract Title & Time SATURDAY, APRIL 16 Using Tumor Biology to Drive Room 288, Morial Convention 9:30am - 9:55am: Immunotherapies for Sarcoma: Crystal Mackall Ludwig Stanford 8:00am - 10:00am Educational Session More Effective Sarcoma Center Progress and Challenges Therapy Room 278, Morial Convention Cancer Immunology for the Crystal Mackall Ludwig Stanford 10:15am -12:15pm Educational Session 10:15am - 12:15pm: Education Manuscript Center Non-Immunologist: Tutorial SUNDAY, APRIL 17 Ovarian cancer Room 343, Morial Convention Meet-the-Expert George Coukos Ludwig Lausanne 7:00am - 8:00am immunotherapy. From bench Invited speaker Center Session to bedside Cellular Plasticity, Cellular Room 288, Morial Convention Meet-the-Expert Xin Lu Ludwig Oxford 7:00am - 8:00am Heterogeneity and Single Cell Invited speaker Center Session Sequencing Stapled Peptides as a New Room 357, Morial Convention Meet-the-Expert Form of Medicine for David Lane Ludwig New York 7:00am - 8:00am Invited speaker Center Session Oncology Targets: Challenges and Progress Room 271, Morial Convention Meet-the-Expert The Role of Metabolism in Matthew Vander Heiden Ludwig MIT 7:00am - 8:00am Invited speaker Center Session Supporting Tumor Growth Thirteenth Annual AACR Award for Lifetime Bob Weinberg Ludwig MIT 8:15am - 9:00am Hall F, Morial Convention Center Awards and Lectures Award recipient Achievement in Cancer Research Thirty-Sixth Annual AACR New Orleans Theater A, Morial Award for Outstanding Award recipient. Presentation title: Biology and Franziska Michor Ludwig Harvard 1:00pm - 2:00pm Awards and Lectures Convention Center Achievement in Cancer dynamics of cancer evolution Research Checkpoint blockade therapy is improved by altering the immune suppressive Olivier De Henau,* Taha Ludwig MSK 1:00pm - 5:00pm Section 26, poster board 15 Poster Session Immune Modulating Agents 1 microenvironment with IPI-549, a potent and Merghoub, Jedd Wolchok selective inhibitor of PI3K-gamma, in preclinical models Mechanisms of Novel refinements for the autochthonous mouse Tyler Jacks** Ludwig MIT 1:00pm - 5:00pm Section 30, poster board 8 Poster Session Tumorigenesis in Animal model of cancer Models of Cancer 1 *denotes scientist is lead author **denotes scientist is senior author 1 Ludwig Presence at 2016 AACR Annual Meeting Ming Zhang, Nicholas Roberts, Christine Joseph, Maria The genomic landscapes of inflammatory bowel Popoli,Kenneth Kinzler, Bert Ludwig Johns Hopkins 1:00pm - 5:00pm Section 5, poster board 11 Poster Session Genomic Profiling of Cancers disease-associated colorectal cancers Vogelstein, Nickolas Papadopoulos** Mitochondrial perturbations as a novel approach Anthony Letai** Ludwig Harvard 1:00pm - 5:00pm Section 20, poster board 24 Poster Session Biomarkers to personalized medicine Pregnancy associated plasma protein A (PAPP- Crystal Mackall** Ludwig Stanford 1:00pm - 5:00pm Section 27, poster board 2 Poster Session Therapeutic Antibodies A) is a potential novel therapeutic target in Ewing sarcoma Implications of Akt inhibition for neoadjuvant Fernanda Koyama*, Anamaria Ludwig Sao Paulo 1:00pm - 5:00pm Section 19, poster board 22 Poster Session PI3K/AKT Inhibitors radiotherapy: improving the rectal cancer Camargo** treatment Genetic Determinants and Excessive HCK kinase activity in the tumor Matthias Ernst* Ludwig Melbourne 1:00pm - 5:00pm Section 25, poster board 13 Poster Session Regulators of Cancer stroma promotes colorectal cancer progression Immunity Genetic Determinants and Identify and prioritize candidate neoantigens from Luis Diaz Ludwig Johns Hopkins 1:00pm - 5:00pm Section 25, poster board 5 Poster Session Regulators of Cancer cancer exome sequencing with unmatched Immunity accuracy Checkpoint blockade therapy is improved by altering the immune suppressive Olivier De Henau,* Taha Ludwig MSK 1:00pm - 5:00pm Section 26, poster board 15 Poster Session Immune Modulating Agents 1 microenvironment with IPI-549, a potent and Merghoub, Jedd Wolchok selective inhibitor of PI3K-gamma, in preclinical models 3:15pm - 3:35pm: A phase I study of an HLA- La Nouvelle Orleans Ballroom, Clinical Trials Plenary Immuno-oncology Clinical Pierre van der Bruggen Ludwig Brussels 2:15pm - 4:15pm DPB1*0401-restricted T-cell receptor targeting Morial Convention Center Session Trials I MAGE-A3 for patients with metastatic cancer AACR-Bayard D. Clarkson Room 393, Morial Convention 2:55pm - 3:20pm: Normal and neoplastic stem Irv Weissman Ludwig Stanford 2:15pm - 4:00pm Major Symposium Symposium: Tumor Cell of Center cells Origin and Cancer Stem Cells 2:00pm - 4:15pm: Durable, long-term survival in La Nouvelle Orleans Ballroom, Clinical Trials Plenary Immuno-oncology Clinical previously treated patients with advanced Stephen Hodi* Ludwig Harvard 2:15pm - 4:15pm Morial Convention Center Session Trials I melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial 2:00pm - 4:15pm: Initial report of overall survival rates from a randomized phase II trial evaluating Michael Postow,* Jedd Wolchok, Ludwig MSK; Ludwig La Nouvelle Orleans Ballroom, Clinical Trials Plenary Immuno-oncology Clinical 2:15pm - 4:15pm the combination of nivolumab (NIVO) and Stephen Hodi** Harvard Morial Convention Center Session Trials I ipilimumab (IPI) in patients with advanced melanoma (MEL) Inflammation and Cancer: Room 293, Morial Convention 2:55pm - 3:20pm: Deciphering mechanisms of Johanna Joyce Ludwig Lausanne 2:15pm - 4:00pm Major Symposium Targeting the Myeloid Center resistance to macrophage-targeted therapies Microenvironment *denotes scientist is lead author **denotes scientist is senior author 2 Ludwig Presence at 2016 AACR Annual Meeting 2:55pm - 3:20pm: Co-targeting epigenetic New Orleans Theater A, Morial Epigenetics and Signaling in Karen Chichowski (Chairperson) Ludwig Harvard 2:15pm - 4:00pm Major Symposium regulators and oncogenic signaling pathways in Convention Center Cancer cancer Room 288, Morial Convention 2:25pm - 2:50pm: Stem cells and signaling Philip Beachy Ludwig Stanford 2:15pm - 4:00pm Major Symposium Developmental Pathways Center pathways in regeneration and malignancy Disordered Gene Regulation 4:35pm - 4:50pm: TMPRSS2-ERG drives global Room 343, Morial Convention Cigall Kadoch** Ludwig Harvard 4:15pm - 6:15pm Minisymposium and Chromatin State in mistargeting of mammalian SWI/SNF (BAF) Center Malignant Transformation complexes in prostate cancer 5:05pm - 5:20pm: Obesity-induced inflammation Joao Incio,* Keehoon Jung, Dai Room 288, Morial Convention Highlights in Cancer Ludwig Harvard 4:15pm - 6:15pm Minisymposium and desmoplasia promote pancreatic cancer Fukumura, Rakesh Jain** Center Prevention Advances progression and resistance to chemotherapy Tumor Microenvironment Mardi Gras Ballroom D-E, New 6:15pm - 6:30pm - Chariperson elect: Remarks; Johanna Joyce Ludwig Lausanne 6:00pm - 8:00pm Town Meeting Working Group (TME) Town Orleans Marriott 7:30pm - 7:35pm - Closing Remarks Hall Meeting and Reception AACR Pediatric Cancer Grand Salon B, Hilton New Working Group Town Hall Crystal Mackall Ludwig Stanford 6:30pm - 9:30pm Town Meeting 6:40pm - 7:30pm: Panelist Orleans Riverside Meeting and Networking Reception MONDAY, APRIL 18 Ya-Fang Chang,* Yuhao Wang, Targeting nuclear receptors and their Ludwig Chicago 8:00am - 12:00pm Section 17, poster board 13 Poster Session Novel Molecular Targets Geoffrey Greene** coregulators in triple-negative breast cancer Discovery and preclinical development of a highly Mersana Therapeutics: Growth Factor Receptors and potent NaPi2b-targeted antibody-drug conjugate research conducted with 8:00am -12:00pm Section 15, poster board 3 Poster Session Surface Antigens as (ADC) with significant activity in patient-derived Ludwig licensed Therapeutic Targets non-small cell lung cancer (NSCLC) xenograft technology models A phase I, open-label study of GSK3174998 Phase I Clinical Trials in administered alone and in combination with Stephen Hodi Ludwig Harvard 8:00am -12:00pm Section 13 Poster Session Progress pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1) Surojit Sur,* Yuan Qiao, Anja PRINT: A protein bioconjugation method with Fries, Kenneth Kinzler, Bert Ludwig Johns Hopkins 8:00am - 12:00pm Section 19, poster board 30 Poster Session Drug Delivery 1 exquisite N-terminal specificity Vogelstein, Shibin Zhou** Surojit Sur,* Kenneth Kinzler, PRINT: A protein bioconjugation method with Ludwig Johns Hopkins 8:00am - 12:00pm Section 19, poster board 30 Poster Session Drug Delivery 1 Bert Vogelstein, Shibin Zhou** exquisite N-terminal specificity *denotes scientist is lead author **denotes scientist is senior author 3 Ludwig Presence at 2016 AACR Annual Meeting Discovery of new AML and MDS patient subsets sensitive to the highly selective RARα agonist SY- Ravindra Majeti Ludwig Stanford 8:00am - 12:00pm Section 14, poster board 7 Poster Session Differentiation Therapy 1425 (tamibarotene) through super-enhancer analysis Immune Microenvironment IL-18 is associated with the onset and Matthias Ernst Ludwig Melbourne 8:00am - 12:00pm Section 24, poster board 4 Poster Session and Antitumor Immunity progression of gastric cancer Genomic Insights Into 11:30am -11:55am: Noninvasive lymphoma Room 288, Morial Convention Recent Advances in Ash Alizadeh Ludwig Stanford 10:30am - 12:15pm Lymphoma Pathogenesis, genotyping and personalized monitoring using Center Organ Site Research